Eris Lifesciences
Stock Snapshot
Price Performance
Vista Outlook
View Technicals Analysis →Basis of our Recommendation
Eris Lifesciences is navigating a complex landscape characterized by both growth opportunities and near-term challenges. Management has highlighted a strategic focus on expanding its insulin portfolio, particularly with the upcoming launch of five insulin products aimed at capturing a growing market segment. This aligns with Vista's forecast of stable revenue growth, supported by the company's strong domestic performance in chronic therapies. However, the current decline in the insulin market and regulatory headwinds in international operations pose risks to achieving these targets. The anticipated completion of facility remediation and the launch of new high-margin products are expected to enhance operational efficiency and profitability in the long term. Despite margin pressures in the near term, particularly from remediation costs, the overall outlook remains cautiously optimistic, with a projected EBITDA margin stabilization in the second half of FY27. Industry dynamics, including improving pricing power and a favorable currency environment, further support Eris's growth trajectory. Key opportunities include the successful commercialization of new products and operational improvements, while watchpoints include regulatory compliance and market adoption rates for new therapies over the next 12-24 months
Why We Like This Stock
- Strategic expansion into the insulin market with a robust product pipeline is expected to drive revenue growth
- Operational improvements from the Bhopal facility are anticipated to enhance margins starting in FY27
- The domestic branded formulation segment shows resilience, particularly in diabetes and GLP-1 categories
Things To Watch Out For
- Regulatory compliance issues and remediation costs are likely to pressure margins in the near term
- The current insulin market segment is experiencing a decline, which could hinder growth prospects
- Delayed product launches and supply constraints may impact revenue generation and market share gains
Key Parameters
Financial Snapshot
| Actuals | Forecast | ||||
|---|---|---|---|---|---|
| FY24 | FY25 | FY26 | FY27 | FY28 | |
| Revenue (Cr.) | 2,009 | 2,894 | 3,129 | 3,111 | 3,547 |
| Profit Before Tax (Cr.) | 428 | 487 | 656 | 723 | 855 |
| PBT Margin | 21.3% | 16.8% | 2096.5% | 23.2% | 24.1% |
| Net Profit (Cr.) | 346 | 375 | 495 | 542 | 605 |
| Earnings Per Share | 24.6 | 25.4 | 33.7 | 36.9 | 43.6 |
Analyst Recommendations
| Broker | Recommendation | Target Price | Date |
|---|---|---|---|
| HDFC Securities | ▲ Buy | 1,730 | 30-Jul-2026 |
| Macguire | ▲ Buy | 1,680 | 22-Apr-2026 |
| Morgan Stanley | ► Neutral | 1,425 | 30-Jul-2026 |
| Motilal Oswal | ► Neutral | 1,435 | 30-Jul-2026 |
| Prabhudas Liladhar | ▲ Buy | 1,700 | 30-Jul-2026 |
Company Overview
Show Company Profile
Eris Lifesciences Limited, together with its subsidiaries, provides domestic branded formulations for chronic and sub-chronic therapies in India and internationally. The company offers various branded formulations in various therapeutic areas, such as antidiabetes, cardiovascular, nutrition, dermatology, neuroscience, gynecology, nephrology, and oncology, as well as central nervous system, women's health, and vitamins/minerals/nutrients. It also provides patient care services, including ambulatory blood pressure measurement, ambulatory electrocardiogram measurement, continuous glucose monitoring system, sleep study, and anti-natal care solutions. It offers its products through wholesale drug distributors, stockists, retail and e-commerce pharmacies. Eris Lifesciences Limited was incorporated in 2007 and is headquartered in Ahmedabad, India.